{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:58:41Z","timestamp":1781585921642,"version":"3.54.5"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10741-020-10028-y","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T18:02:51Z","timestamp":1602093771000},"page":"679-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review"],"prefix":"10.1007","volume":"26","author":[{"given":"Fatemeh","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsane Maddah","family":"Safaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Asadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara Molanaie","family":"Kamangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zadehbagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-5851","authenticated-orcid":false,"given":"Nahid","family":"Rezaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"10028_CR1","doi-asserted-by":"publisher","unstructured":"Carreras G, Lachi A, Boffi R et al (2020) Burden of disease from breast cancer attributable to smoking and second-hand smoke exposure in Europe. Int J Cancer:ijc.33021. https:\/\/doi.org\/10.1002\/ijc.33021","DOI":"10.1002\/ijc.33021"},{"key":"10028_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-004-3777-3","volume":"90","author":"WF Anderson","year":"2005","unstructured":"Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI\u2019s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127\u2013137. https:\/\/doi.org\/10.1007\/s10549-004-3777-3","journal-title":"Breast Cancer Res Treat"},{"key":"10028_CR3","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Carbonell X, Casta\u00f1eda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162\u20132171. https:\/\/doi.org\/10.1200\/JCO.2005.01.014","journal-title":"J Clin Oncol"},{"key":"10028_CR4","first-page":"15","volume":"11","author":"F Cai","year":"2019","unstructured":"Cai F, Luis MAF, Lin X et al (2019) Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol 11:15\u201323","journal-title":"Mol Clin Oncol"},{"key":"10028_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504\u20132512. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077\u20131084. https:\/\/doi.org\/10.1056\/NEJM200004133421502","journal-title":"N Engl J Med"},{"key":"10028_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","volume":"6","author":"P Thavendiranathan","year":"2013","unstructured":"Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH (2013) Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review. Circ Cardiovasc Imaging 6:1080\u20131091","journal-title":"Circ Cardiovasc Imaging"},{"key":"10028_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-041316-090622","volume":"69","author":"V Narayan","year":"2018","unstructured":"Narayan V, Ky B (2018) Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention. Annu Rev Med 69:97\u2013111. https:\/\/doi.org\/10.1146\/annurev-med-041316-090622","journal-title":"Annu Rev Med"},{"key":"10028_CR9","unstructured":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2802286\/. Accessed 1 Aug 2020"},{"key":"10028_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122\u20131130. https:\/\/doi.org\/10.1200\/JCO.2015.64.0409","journal-title":"J Clin Oncol"},{"key":"10028_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375:1457\u20131467","journal-title":"N Engl J Med"},{"key":"10028_CR12","unstructured":"Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin cyclophosphamide, streptozotocin and bevacizumab | Request PDF. https:\/\/www.researchgate.net\/publication\/6639516_Cardiovascular_toxicity_of_the_first_line_cancer_chemotherapeutic_agents_Doxorubicin_cyclophosphamide_streptozotocin_and_bevacizumab. Accessed 1 Aug 2020"},{"key":"10028_CR13","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 70:2536\u20132551","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR14","doi-asserted-by":"publisher","unstructured":"Jolly MP, Jordan JH, Mel\u00e9ndez GC, McNeal GR, D\u2019Agostino RB Jr, Hundley WG (2017) Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson 19. https:\/\/doi.org\/10.1186\/s12968-017-0373-3","DOI":"10.1186\/s12968-017-0373-3"},{"key":"10028_CR15","doi-asserted-by":"publisher","unstructured":"Pituskin E, Haykowsky M, Mackey JR et al (2011) Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11. https:\/\/doi.org\/10.1186\/1471-2407-11-318","DOI":"10.1186\/1471-2407-11-318"},{"key":"10028_CR16","doi-asserted-by":"crossref","unstructured":"Fanous I, Dillon P (2016) Cancer treatment-related cardiac toxicity: prevention, assessment and management. Med Oncol 33","DOI":"10.1007\/s12032-016-0801-5"},{"key":"10028_CR17","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.2217\/fon.15.227","volume":"11","author":"G Jerusalem","year":"2015","unstructured":"Jerusalem G, Moonen M, Freres P, Lancellotti P (2015) The European Association of Cardiovascular Imaging\/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment. Future Oncol 11:2791\u20132794. https:\/\/doi.org\/10.2217\/fon.15.227","journal-title":"Future Oncol"},{"key":"10028_CR18","doi-asserted-by":"publisher","first-page":"e0199529","DOI":"10.1371\/journal.pone.0199529","volume":"13","author":"E Depardon","year":"2018","unstructured":"Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A (2018) FDG PET\/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: comparison of EORTC criteria and PERCIST. PLoS One 13:e0199529. https:\/\/doi.org\/10.1371\/journal.pone.0199529","journal-title":"PLoS One"},{"key":"10028_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0749-3797(98)00045-2","volume":"15","author":"J Parker","year":"1998","unstructured":"Parker J, Gebretsadik T, Sabogal F, Newman J, Lawson HW (1998) Mammography screening among California Medicare beneficiaries: 1993- 1994. Am J Prev Med 15:198\u2013205. https:\/\/doi.org\/10.1016\/S0749-3797(98)00045-2","journal-title":"Am J Prev Med"},{"key":"10028_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","volume":"16","author":"S Martel","year":"2017","unstructured":"Martel S, Maurer C, Lambertini M, Pond\u00e9 N, de Azambuja E (2017) Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf 16:1021\u20131038","journal-title":"Expert Opin Drug Saf"},{"key":"10028_CR21","doi-asserted-by":"publisher","unstructured":"Yoon HJ, Kim HN, Yun Y et al (2015) Background intestinal 18F-FDG uptake is related to serum lipid profile and obesity in breast cancer patients. PLoS One 10. https:\/\/doi.org\/10.1371\/journal.pone.0141473","DOI":"10.1371\/journal.pone.0141473"},{"key":"10028_CR22","doi-asserted-by":"publisher","first-page":"e0220644","DOI":"10.1371\/journal.pone.0220644","volume":"14","author":"S Di Cosimo","year":"2019","unstructured":"Di Cosimo S, La Verde N, Moretti A et al (2019) Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: results from the HOPE study. PLoS One 14:e0220644. https:\/\/doi.org\/10.1371\/journal.pone.0220644","journal-title":"PLoS One"},{"key":"10028_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-012-2185-3","volume":"135","author":"H Razzaghi","year":"2012","unstructured":"Razzaghi H, Troester MA, Gierach GL, Olshan AF, Yankaskas BC, Millikan RC (2012) Mammographic density and breast cancer risk in White and African American Women. Breast Cancer Res Treat 135:571\u2013580. https:\/\/doi.org\/10.1007\/s10549-012-2185-3","journal-title":"Breast Cancer Res Treat"},{"key":"10028_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1634\/theoncologist.2016-0334","volume":"22","author":"S Chen","year":"2017","unstructured":"Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC (2017) Complete metabolic response on interim 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography to predict long-term survival in patients with breast cancer undergoing neoadjuvant chemotherapy. Oncologist 22:526\u2013534. https:\/\/doi.org\/10.1634\/theoncologist.2016-0334","journal-title":"Oncologist"},{"key":"10028_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","volume":"108","author":"HJ Yoon","year":"2019","unstructured":"Yoon HJ, Kim KH, Kim HY, Park H, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC (2019) Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 108:892\u2013900. https:\/\/doi.org\/10.1007\/s00392-019-01417-x","journal-title":"Clin Res Cardiol"},{"key":"10028_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s0213-9111(97)71279-2","volume":"11","author":"X Bonfill","year":"1997","unstructured":"Bonfill X, Roura P, Moreno C, Rivero E, Ru\u00e9 M (1997) Cancer mortality in the counties of Catalonia (1983-1989). Gac Sanit 11:74\u201382. https:\/\/doi.org\/10.1016\/s0213-9111(97)71279-2","journal-title":"Gac Sanit"},{"key":"10028_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-005-9093-8","volume":"97","author":"A Krishnaraj","year":"2006","unstructured":"Krishnaraj A, Yankaskas BC, Stearns SC (2006) Screening mammography after breast cancer treatment: patterns in community practice. Breast Cancer Res Treat 97:73\u201380","journal-title":"Breast Cancer Res Treat"},{"key":"10028_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.biopha.2009.04.043","volume":"63","author":"M Landau-Ossondo","year":"2009","unstructured":"Landau-Ossondo M, Rabia N, Jos-Pelage J, Marquet LM, Isidore Y, Saint-Aim\u00e9 C, Martin M, Irigaray P, Belpomme D, ARTAC international research group on pesticides (2009) Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer. Biomed Pharmacother 63:383\u2013395","journal-title":"Biomed Pharmacother"},{"key":"10028_CR29","doi-asserted-by":"crossref","unstructured":"Boerma M (2018) Cardiovascular side effects of breast cancer therapy. In: Gender Differences in the pathogenesis and management of heart disease. Springer International Publishing, pp 303\u2013316","DOI":"10.1007\/978-3-319-71135-5_17"},{"key":"10028_CR30","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.7314\/apjcp.2015.16.8.3559","volume":"16","author":"A Imene","year":"2015","unstructured":"Imene A, Maurice AJ, Arij M et al (2015) Breast cancer association with CYP1A2 activity and gene polymorphisms--a preliminary case-control study in Tunisia. Asian Pac J Cancer Prev 16:3559\u20133563. https:\/\/doi.org\/10.7314\/apjcp.2015.16.8.3559","journal-title":"Asian Pac J Cancer Prev"},{"key":"10028_CR31","unstructured":"Radiotherapy effects on systolic myocardial function detected by strain rate imaging in a left-breast cancer patient - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/17673445\/. Accessed 1 Aug 2020"},{"key":"10028_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2478\/raon-2013-0040","volume":"48","author":"T Marinko","year":"2014","unstructured":"Marinko T, Dolenc J, Bilban-Jakopin C (2014) Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 48:105\u2013112","journal-title":"Radiol Oncol"},{"key":"10028_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14740338.2016.1182493","volume":"15","author":"G Giordano","year":"2016","unstructured":"Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, Villari B, Febbraro A (2016) Cancer drug related cardiotoxicity during breast cancer treatment. Expert Opin Drug Saf 15:1063\u20131074","journal-title":"Expert Opin Drug Saf"},{"key":"10028_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2016.71.0038","volume":"35","author":"P Thavendiranathan","year":"2017","unstructured":"Thavendiranathan P, Amir E (2017) Left ventricular dysfunction with trastuzumab therapy: is primary prevention the best option? J Clin Oncol 35:820\u2013825. https:\/\/doi.org\/10.1200\/JCO.2016.71.0038","journal-title":"J Clin Oncol"},{"key":"10028_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HCO.0b013e3283570040","volume":"27","author":"A Singla","year":"2012","unstructured":"Singla A, Kumar G, Bardia A (2012) Personalizing cardiovascular disease prevention among breast cancer survivors. Curr Opin Cardiol 27:1. https:\/\/doi.org\/10.1097\/HCO.0b013e3283570040","journal-title":"Curr Opin Cardiol"},{"key":"10028_CR36","doi-asserted-by":"publisher","unstructured":"Nicolazzi MA, Carnicelli A, Fuorlo M et al (2018) Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci 22. https:\/\/doi.org\/10.26355\/EURREV_201804_14752","DOI":"10.26355\/EURREV_201804_14752"},{"key":"10028_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","volume":"34","author":"RS Copeland-Halperin","year":"2019","unstructured":"Copeland-Halperin RS, Liu JE, Yu AF (2019) Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol 34:451\u2013458","journal-title":"Curr Opin Cardiol"},{"key":"10028_CR38","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1249\/MSS.0000000000001970","volume":"51","author":"SJ Foulkes","year":"2019","unstructured":"Foulkes SJ, Howden EJ, Bigaran A et al (2019) Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy. Med Sci Sports Exerc 51:1573\u20131581. https:\/\/doi.org\/10.1249\/MSS.0000000000001970","journal-title":"Med Sci Sports Exerc"},{"key":"10028_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","volume":"76","author":"SC Darby","year":"2010","unstructured":"Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ETH, Shore RE (2010) Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76:656\u2013665","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10028_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Br\u00f8nnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987\u2013998. https:\/\/doi.org\/10.1056\/NEJMoa1209825","journal-title":"N Engl J Med"},{"key":"10028_CR41","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","volume":"35","author":"VAB Van Den Bogaard","year":"2017","unstructured":"Van Den Bogaard VAB, Ta BDP, Van Der Schaaf A et al (2017) Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 35:1171\u20131178. https:\/\/doi.org\/10.1200\/JCO.2016.69.8480","journal-title":"J Clin Oncol"},{"key":"10028_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1259\/bjr.74.879.740262","volume":"74","author":"PA Canney","year":"2001","unstructured":"Canney PA, Sanderson R, Deehan C, Wheldon T (2001) Variation in the probability of cardiac complications with radiation technique in early breast cancer. Br J Radiol 74:262\u2013265. https:\/\/doi.org\/10.1259\/bjr.74.879.740262","journal-title":"Br J Radiol"},{"key":"10028_CR43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/2012.jama.10759","volume":"308","author":"SC Formenti","year":"2012","unstructured":"Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD (2012) Prone vs supine positioning for breast cancer radiotherapy. JAMA 308:861\u2013863","journal-title":"JAMA"},{"key":"10028_CR44","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0360-3016(00)00512-5","volume":"47","author":"HM Lu","year":"2000","unstructured":"Lu HM, Cash E, Chen MH, Chin L, Manning WJ, Harris J, Bornstein B (2000) Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study. Int J Radiat Oncol Biol Phys 47:895\u2013904. https:\/\/doi.org\/10.1016\/S0360-3016(00)00512-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10028_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/CCO.V0I0.10584","volume":"5","author":"A Chhabra","year":"2016","unstructured":"Chhabra A, Langen K, Mehta MP (2016) An overview of modern proton therapy. Chinese. Clin Oncol 5:2. https:\/\/doi.org\/10.21037\/CCO.V0I0.10584","journal-title":"Clin Oncol"},{"key":"10028_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jmri.25053","volume":"43","author":"V Dunet","year":"2016","unstructured":"Dunet V, Schwitter J, Meuli R, Beigelman-Aubry C (2016) Incidental extracardiac findings on cardiac MR: systematic review and meta-analysis. J Magn Reson Imaging 43:929\u2013939","journal-title":"J Magn Reson Imaging"},{"key":"10028_CR47","unstructured":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/26903532\/. Accessed 6 Aug 2020"},{"key":"10028_CR48","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"key":"10028_CR49","doi-asserted-by":"crossref","unstructured":"Tuzovic M, Agarwal M, Thareja N, Yang EH (2019) Cardiac Toxicity of HER-2 Targeted Regimens","DOI":"10.1016\/B978-0-323-58122-6.00010-6"},{"key":"10028_CR50","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P, International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475\u20131487","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR51","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jcmg.2012.01.016","volume":"5","author":"M Ugander","year":"2012","unstructured":"Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE (2012) Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging 5:596\u2013603. https:\/\/doi.org\/10.1016\/j.jcmg.2012.01.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.13121239","volume":"268","author":"M Motwani","year":"2013","unstructured":"Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, Plein S (2013) MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 268:26\u201343","journal-title":"Radiology"},{"key":"10028_CR53","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158\u20133176","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR54","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1067\/mhj.2001.115436","volume":"141","author":"R Wassmuth","year":"2001","unstructured":"Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG (2001) Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 141:1007\u20131013. https:\/\/doi.org\/10.1067\/mhj.2001.115436","journal-title":"Am Heart J"},{"key":"10028_CR55","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","volume":"70","author":"C Gr\u00e4ni","year":"2017","unstructured":"Gr\u00e4ni C, Eichhorn C, Bi\u00e8re L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY (2017) Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70:1964\u20131976. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.050","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR56","doi-asserted-by":"publisher","unstructured":"Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, Bittencourt MS, Murthy VL, Kwong R, di Carli MF, Blankstein R (2016) Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-Analysis. Circ Cardiovasc Imaging 9. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005001","DOI":"10.1161\/CIRCIMAGING.116.005001"},{"key":"10028_CR57","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","volume":"56","author":"R O\u2019Hanlon","year":"2010","unstructured":"O\u2019Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867\u2013874. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.010","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/COC.0b013e31829e19be","volume":"38","author":"MA Lunning","year":"2015","unstructured":"Lunning MA, Kutty S, Rome ET, Li L, Padiyath A, Loberiza F, Bociek RG, Bierman PJ, Vose JM, Armitage JO, Porter TR (2015) Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy. Am J Clin Oncol 38:377\u2013381. https:\/\/doi.org\/10.1097\/COC.0b013e31829e19be","journal-title":"Am J Clin Oncol"},{"key":"10028_CR59","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"N Fallah-Rad","year":"2011","unstructured":"Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick IDC, Singal PK, Krahn M, Grenier D, Jassal DS (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor iipositive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57:2263\u20132270. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.063","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/01913129409016291","volume":"18","author":"B Mackay","year":"1994","unstructured":"Mackay B, Ewer MS, Carrasco CH, Benjamin RS (1994) Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203\u2013211. https:\/\/doi.org\/10.3109\/01913129409016291","journal-title":"Ultrastruct Pathol"},{"key":"10028_CR61","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.carpath.2009.07.004","volume":"19","author":"BN Bernaba","year":"2010","unstructured":"Bernaba BN, Chan JB, Lai CK, Fishbein MC (2010) Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol 19:308\u2013311. https:\/\/doi.org\/10.1016\/j.carpath.2009.07.004","journal-title":"Cardiovasc Pathol"},{"key":"10028_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12968-015-0172-7","volume":"17","author":"KS Nayak","year":"2015","unstructured":"Nayak KS, Nielsen JF, Bernstein MA, Markl M, D. Gatehouse P, M. Botnar R, Saloner D, Lorenz C, Wen H, S. Hu B, Epstein FH, N. Oshinski J, Raman SV (2015) Cardiovascular magnetic resonance phase contrast imaging. J Cardiovasc Magn Reson 17:71","journal-title":"J Cardiovasc Magn Reson"},{"key":"10028_CR63","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2009.23.8527","volume":"28","author":"N Chaosuwannakit","year":"2010","unstructured":"Chaosuwannakit N, D\u2019Agostino R, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166\u2013172. https:\/\/doi.org\/10.1200\/JCO.2009.23.8527","journal-title":"J Clin Oncol"},{"key":"10028_CR64","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","volume":"6","author":"BC Drafts","year":"2013","unstructured":"Drafts BC, Twomley KM, D\u2019Agostino R et al (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6:877\u2013885. https:\/\/doi.org\/10.1016\/j.jcmg.2012.11.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR65","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3810\/pgm.2011.05.2295","volume":"123","author":"R Chotenimitkhun","year":"2011","unstructured":"Chotenimitkhun R, Gregory Hundley W (2011) Pharmacological stress cardiovascular magnetic resonance. Postgrad Med 123:162\u2013170. https:\/\/doi.org\/10.3810\/pgm.2011.05.2295","journal-title":"Postgrad Med"},{"key":"10028_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1532-429X-15-91","volume":"15","author":"CM Kramer","year":"2013","unstructured":"Kramer CM, Barkhausen J, Flamm SD et al (2013) Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 15:91","journal-title":"J Cardiovasc Magn Reson"},{"key":"10028_CR67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jaccao.2020.04.011","volume":"2","author":"I Harries","year":"2020","unstructured":"Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C (2020) Magnetic resonance imaging to detect cardiovascular effects of cancer therapy. JACC: CardioOncology 2:270\u2013292. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.011","journal-title":"JACC: CardioOncology"},{"key":"10028_CR68","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijcard.2018.03.041","volume":"261","author":"G Ong","year":"2018","unstructured":"Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Chow CM, Thavendiranathan D, Haq R, Barfett JJ, Petrella TM, Connelly KA, Yan AT (2018) Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol 261:228\u2013233. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.041","journal-title":"Int J Cardiol"},{"key":"10028_CR69","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 27:911\u2013939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"key":"10028_CR70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.echo.2012.04.007","volume":"25","author":"JT Poterucha","year":"2012","unstructured":"Poterucha JT, Kutty S, Lindquist RK, Li L, Eidem BW (2012) Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr 25:733\u2013740. https:\/\/doi.org\/10.1016\/j.echo.2012.04.007","journal-title":"J Am Soc Echocardiogr"},{"key":"10028_CR71","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","volume":"26","author":"K Negishi","year":"2013","unstructured":"Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493\u2013498. https:\/\/doi.org\/10.1016\/j.echo.2013.02.008","journal-title":"J Am Soc Echocardiogr"},{"key":"10028_CR72","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.117.027930","volume":"135","author":"JH Jordan","year":"2017","unstructured":"Jordan JH, Sukpraphrute B, Mel\u00e9ndez GC, Jolly MP, D\u2019Agostino RB Jr, Hundley WG (2017) Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: the need to interpret left ventricular strain with volumes. Circulation 135:2575\u20132577","journal-title":"Circulation"},{"key":"10028_CR73","doi-asserted-by":"publisher","first-page":"P273","DOI":"10.1186\/1532-429x-16-s1-p273","volume":"16","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Amir E, Bedard P, Crean A, Paul N, Nguyen ET, Wintersperger BJ (2014) Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab. J Cardiovasc Magn Reson 16:P273. https:\/\/doi.org\/10.1186\/1532-429x-16-s1-p273","journal-title":"J Cardiovasc Magn Reson"},{"key":"10028_CR74","unstructured":"Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/17159809\/. Accessed 1 Aug 2020"},{"key":"10028_CR75","doi-asserted-by":"publisher","unstructured":"Salerno M, Sharif B, Arheden H, Kumar A, Axel L, Li D, Neubauer S (2017) Recent advances in cardiovascular magnetic resonance. Circ Cardiovasc Imaging 10. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.003951","DOI":"10.1161\/CIRCIMAGING.116.003951"},{"key":"10028_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcmg.2015.11.005","volume":"9","author":"AJ Taylor","year":"2016","unstructured":"Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M (2016) T1 mapping basic techniques and clinical applications. JACC Cardiovasc Imaging 9:67\u201381","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR77","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jcmg.2015.11.014","volume":"9","author":"F B\u00f6nner","year":"2016","unstructured":"B\u00f6nner F, Spieker M, Haberkorn S et al (2016) Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis. JACC Cardiovasc Imaging 9:1467\u20131469","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR78","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1161\/01.CIR.0000127428.10985.C6","volume":"109","author":"H Abdel-Aty","year":"2004","unstructured":"Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, Gross M, Dietz R, Friedrich MG (2004) Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 109:2411\u20132416. https:\/\/doi.org\/10.1161\/01.CIR.0000127428.10985.C6","journal-title":"Circulation"},{"key":"10028_CR79","doi-asserted-by":"crossref","unstructured":"Haaf P, Garg P, Messroghli DR et al (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18","DOI":"10.1186\/s12968-016-0308-4"},{"key":"10028_CR80","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","volume":"111","author":"TG Neilan","year":"2013","unstructured":"Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M (2013) Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 111:717\u2013722. https:\/\/doi.org\/10.1016\/j.amjcard.2012.11.022","journal-title":"Am J Cardiol"},{"key":"10028_CR81","unstructured":"An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/24675088\/. Accessed 6 Aug 2020"},{"key":"10028_CR82","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","volume":"30","author":"GT Armstrong","year":"2012","unstructured":"Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30:2876\u20132884. https:\/\/doi.org\/10.1200\/JCO.2011.40.3584","journal-title":"J Clin Oncol"},{"key":"10028_CR83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1743-7563.2011.01462.x","volume":"8","author":"C Lawley","year":"2012","unstructured":"Lawley C, Wainwright C, Segelov E et al (2012) Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. Asia Pac J Clin Oncol 8:95\u2013100. https:\/\/doi.org\/10.1111\/j.1743-7563.2011.01462.x","journal-title":"Asia Pac J Clin Oncol"},{"key":"10028_CR84","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","volume":"28","author":"J Walker","year":"2010","unstructured":"Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, Summers AR, Singal PK, Barac I, Kirkpatrick ID, Jassal DS (2010) Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28:3429\u20133436. https:\/\/doi.org\/10.1200\/JCO.2009.26.7294","journal-title":"J Clin Oncol"},{"key":"10028_CR85","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10554-019-01648-z","volume":"35","author":"V Dhir","year":"2019","unstructured":"Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, Haq R, Kirpalani A, Chan KKW, Petrella TM, Brezden-Masley C (2019) Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging 35:2085\u20132093. https:\/\/doi.org\/10.1007\/s10554-019-01648-z","journal-title":"Int J Cardiovasc Imaging"},{"key":"10028_CR86","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5603\/CJ.a2016.0023","volume":"23","author":"S Nakano","year":"2016","unstructured":"Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S (2016) Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: a pilot study to evaluate the feasibility of the method. Cardiol J 23:270\u2013280. https:\/\/doi.org\/10.5603\/CJ.a2016.0023","journal-title":"Cardiol J"},{"key":"10028_CR87","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.amjcard.2018.12.046","volume":"123","author":"L Song","year":"2019","unstructured":"Song L, Brezden-Masley C, Ramanan V, Ghugre N, Barfett JJ, Chan KKW, Haq R, Petrella T, Dhir V, Jimenez-Juan L, Chacko BR, Kotha V, Connelly KA, Yan AT (2019) Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab. Am J Cardiol 123:1173\u20131179. https:\/\/doi.org\/10.1016\/j.amjcard.2018.12.046","journal-title":"Am J Cardiol"},{"key":"10028_CR88","unstructured":"CMR in the Evaluation of LV Diastolic Dysfunction - American College of Cardiology. https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2020\/01\/10\/11\/30\/cmr-in-the-evaluation-of-diastolic-dysfunction. Accessed 6 Aug 2020"},{"key":"10028_CR89","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","volume":"135","author":"H Saiki","year":"2017","unstructured":"Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, Ruddy KJ, Yan E, Redfield MM (2017) Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135:1388\u20131396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025434","journal-title":"Circulation"},{"key":"10028_CR90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.md.0000199556.69588.8e","volume":"85","author":"S Ben-Horin","year":"2006","unstructured":"Ben-Horin S, Banke I, Guetta V, Livneh A (2006) Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. Medicine 85:49\u201353. https:\/\/doi.org\/10.1097\/01.md.0000199556.69588.8e","journal-title":"Medicine"},{"key":"10028_CR91","doi-asserted-by":"publisher","unstructured":"Barthur A, Brezden-Masley C, Connelly KA, Dhir V, Chan KKW, Haq R, Kirpalani A, Barfett JJ, Jimenez-Juan L, Karur GR, Deva DP, Yan AT (2017) Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson 19. https:\/\/doi.org\/10.1186\/s12968-017-0356-4","DOI":"10.1186\/s12968-017-0356-4"},{"key":"10028_CR92","doi-asserted-by":"publisher","unstructured":"Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson:10. https:\/\/doi.org\/10.1186\/1532-429X-10-5","DOI":"10.1186\/1532-429X-10-5"},{"key":"10028_CR93","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jcmg.2018.05.012","volume":"11","author":"T Ferreira de Souza","year":"2018","unstructured":"Ferreira de Souza T, Quinaglia AC, Silva T, Osorio Costa F et al (2018) Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging 11:1045\u20131055. https:\/\/doi.org\/10.1016\/j.jcmg.2018.05.012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR94","unstructured":"Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/29106497\/. Accessed 1 Aug 2020"},{"key":"10028_CR95","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","volume":"73","author":"C Gal\u00e1n-Arriola","year":"2019","unstructured":"Gal\u00e1n-Arriola C, Lobo M, V\u00edlchez-Tschischke JP, L\u00f3pez GJ, de Molina-Iracheta A, P\u00e9rez-Mart\u00ednez C, Ag\u00fcero J, Fern\u00e1ndez-Jim\u00e9nez R, Mart\u00edn-Garc\u00eda A, Oliver E, Villena-Gutierrez R, Pizarro G, S\u00e1nchez PL, Fuster V, S\u00e1nchez-Gonz\u00e1lez J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779\u2013791. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.046","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR96","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jcmg.2019.10.016","volume":"13","author":"MA Altaha","year":"2020","unstructured":"Altaha MA, Nolan M, Marwick TH, Somerset E, Houbois C, Amir E, Yip P, Connelly KA, Michalowska M, Sussman MS, Wintersperger BJ, Thavendiranathan P (2020) Can quantitative cmr tissue characterization adequately identify cardiotoxicity during chemotherapy?: impact of temporal and observer variability. JACC Cardiovasc Imaging 13:951\u2013962. https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR97","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10554-018-1482-2","volume":"35","author":"IY Gong","year":"2019","unstructured":"Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Graham JJ, Chow CM, Thavendiranathan P, Dai D, Ng MY, Barfett JJ, Connelly KA, Yan AT (2019) Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imaging 35:653\u2013662. https:\/\/doi.org\/10.1007\/s10554-018-1482-2","journal-title":"Int J Cardiovasc Imaging"},{"key":"10028_CR98","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcmg.2012.10.022","volume":"6","author":"R Jasaityte","year":"2013","unstructured":"Jasaityte R, Claus P, Teske AJ, Herbots L, Verheyden B, Jurcut R, Rademakers F, D'hooge J (2013) The slope of the segmental stretch-strain relationship as a noninvasive index of LV inotropy. JACC Cardiovasc Imaging 6:419\u2013428. https:\/\/doi.org\/10.1016\/j.jcmg.2012.10.022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10028_CR99","doi-asserted-by":"publisher","unstructured":"Jordan JH, Vasu S, Morgan TM et al (2016) Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 9. https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.004325","DOI":"10.1161\/CIRCIMAGING.115.004325"},{"key":"10028_CR100","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijcard.2018.03.025","volume":"261","author":"A Kimball","year":"2018","unstructured":"Kimball A, Patil S, Koczwara B, Raman KS, Perry R, Grover S, Selvanayagam J (2018) Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients. Int J Cardiol 261:159\u2013161. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.025","journal-title":"Int J Cardiol"},{"key":"10028_CR101","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552\u20132565","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR102","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1078155216643859","volume":"23","author":"SE Dogan","year":"2017","unstructured":"Dogan SE, Mizrak D, Alkan A, Demirkazik A (2017) Docetaxel-induced pericardial effusion. J Oncol Pharm Pract 23:389\u2013391. https:\/\/doi.org\/10.1177\/1078155216643859","journal-title":"J Oncol Pharm Pract"},{"key":"10028_CR103","unstructured":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC. https:\/\/pubmed.ncbi.nlm.nih.gov\/27567406\/. Accessed 6 Aug 2020"},{"key":"10028_CR104","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijrobp.2017.05.022","volume":"99","author":"MS Ning","year":"2017","unstructured":"Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z (2017) Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 99:70\u201379. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.05.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10028_CR105","unstructured":"Pericardial disease associated with malignancy - UpToDate. https:\/\/www.uptodate.com\/contents\/pericardial-disease-associated-with-malignancy. Accessed 15 Aug 2020"},{"key":"10028_CR106","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2214\/AJR.10.5666","volume":"197","author":"ETD Hoey","year":"2011","unstructured":"Hoey ETD, Gulati GS, Ganeshan A, Watkin RW, Simpson H, Sharma S (2011) Cardiovascular MRI for assessment of infectious and inflammatory conditions of the heart. Am J Roentgenol 197:103\u2013112","journal-title":"Am J Roentgenol"},{"key":"10028_CR107","doi-asserted-by":"crossref","unstructured":"Bogaert J, Francone M (2009) Cardiovascular magnetic resonance in pericardial diseases. J Cardiovasc Magn Reson 11","DOI":"10.1186\/1532-429X-11-14"},{"key":"10028_CR108","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson P, McKenna RW, Bristow M et al (1996) Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841\u2013842","journal-title":"Circulation"},{"key":"10028_CR109","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","volume":"102","author":"DM Gujral","year":"2016","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S (2016) Radiation-induced valvular heart disease. Heart 102:269\u2013276","journal-title":"Heart"},{"key":"10028_CR110","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.bjc.6605191","volume":"101","author":"T Wethal","year":"2009","unstructured":"Wethal T, Lund MB, Edvardsen T, Foss\u00e5 SD, Pripp AH, Holte H, Kjekshus J, Foss\u00e5 A (2009) Valvular dysfunction and left ventricular changes in Hodgkin\u2019s lymphoma survivors. A longitudinal study. Br J Cancer 101:575\u2013581. https:\/\/doi.org\/10.1038\/sj.bjc.6605191","journal-title":"Br J Cancer"},{"key":"10028_CR111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.25122\/jml-2018-0067","volume":"13","author":"HZ Amin","year":"2020","unstructured":"Amin HZ, Amin LZ, Pradipta A (2020) Takotsubo cardiomyopathy: a brief review. J Med Life 13:3\u20137","journal-title":"J Med Life"},{"key":"10028_CR112","doi-asserted-by":"publisher","unstructured":"Desai A, Noor A, Joshi S, Kim AS (2019) Takotsubo cardiomyopathy in cancer patients. https:\/\/doi.org\/10.1186\/s40959-019-0042-9","DOI":"10.1186\/s40959-019-0042-9"},{"key":"10028_CR113","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1111\/j.1524-4741.2010.01004.x","volume":"16","author":"LP Molteni","year":"2010","unstructured":"Molteni LP, Rampinelli I, Cergnul M, Scaglietti U, Paino AM, Noonan DM, Bucci EO, Gottardi O, Albini A (2010) Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 16:S45\u2013S48","journal-title":"Breast J"},{"key":"10028_CR114","doi-asserted-by":"publisher","first-page":"e1188","DOI":"10.1097\/MJT.0000000000000134","volume":"23","author":"A Qasem","year":"2016","unstructured":"Qasem A, Bin Abdulhak AA, Aly A, Moormeier J (2016) Capecitabine-tnduced Takotsubo cardiomyopathy. Am J Ther 23:e1188\u2013e1192. https:\/\/doi.org\/10.1097\/MJT.0000000000000134","journal-title":"Am J Ther"},{"key":"10028_CR115","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.clon.2012.12.007","volume":"25","author":"M Khanji","year":"2013","unstructured":"Khanji M, Nolan S, Gwynne S, Pudney D, Ionescu A (2013) Tako-Tsubo syndrome after trastuzumab - an unusual complication of chemotherapy for breast cancer. Clin Oncol 25:329","journal-title":"Clin Oncol"},{"key":"10028_CR116","doi-asserted-by":"publisher","unstructured":"Balanescu DV, Liu VY, Donisan T et al (2018) P1253Clinical features and outcomes of patients with chemotherapy-induced Takotsubo stress cardiomyopathy. Eur Heart J 39. https:\/\/doi.org\/10.1093\/eurheartj\/ehy565.p1253","DOI":"10.1093\/eurheartj\/ehy565.p1253"},{"key":"10028_CR117","doi-asserted-by":"publisher","unstructured":"Cammann VL, Sarcon A, Ding KJ et al (2019) Clinical features and outcomes of patients with malignancy and Takotsubo syndrome: observations from the International Takotsubo Registry. J Am Heart Assoc 8. https:\/\/doi.org\/10.1161\/JAHA.118.010881","DOI":"10.1161\/JAHA.118.010881"},{"key":"10028_CR118","doi-asserted-by":"publisher","first-page":"58","DOI":"10.15420\/ecr.2017:7:2","volume":"12","author":"K Bratis","year":"2017","unstructured":"Bratis K (2017) Cardiac magnetic resonance in Takotsubo syndrome. Eur Cardiol Rev 12:58\u201362","journal-title":"Eur Cardiol Rev"},{"key":"10028_CR119","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/hrt.69.6.483","volume":"69","author":"REA Smith","year":"1993","unstructured":"Smith REA, Dobbs HJ, Martin JF (1993) Radiotherapy, left-sided breast cancer, and ischaemic heart disease. Br Heart J 69:483\u2013484","journal-title":"Br Heart J"},{"key":"10028_CR120","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Pi\u00f1a IL, Volgman AS (2018) Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137:e30\u2013e66. https:\/\/doi.org\/10.1161\/CIR.0000000000000556","journal-title":"Circulation"},{"key":"10028_CR121","unstructured":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Socie. https:\/\/pubmed.ncbi.nlm.nih.gov\/28886621\/. Accessed 6 Aug 2020"},{"key":"10028_CR122","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"SD Kristensen","year":"2014","unstructured":"Kristensen SD, Knuuti J, Saraste A, Anker S, B\u00f8tker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, L\u00fcscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C, Authors\/Task Force Members (2014) 2014 ESC\/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 35:2383\u20132431. https:\/\/doi.org\/10.1093\/eurheartj\/ehu282","journal-title":"Eur Heart J"},{"key":"10028_CR123","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/djk064","volume":"99","author":"MJ Hooning","year":"2007","unstructured":"Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, Taylor CW, van Leeuwen FE (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365\u2013375. https:\/\/doi.org\/10.1093\/jnci\/djk064","journal-title":"J Natl Cancer Inst"},{"key":"10028_CR124","doi-asserted-by":"crossref","unstructured":"Stewart MH, Jahangir E, Polin NM (2017) Valvular heart disease in cancer patients: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med 19","DOI":"10.1007\/s11936-017-0550-6"},{"key":"10028_CR125","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","volume":"42","author":"PA Heidenreich","year":"2003","unstructured":"Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I (2003) Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743\u2013749. https:\/\/doi.org\/10.1016\/S0735-1097(03)00759-9","journal-title":"J Am Coll Cardiol"},{"key":"10028_CR126","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/s0003-4975(98)00082-4","volume":"65","author":"RS Veeragandham","year":"1998","unstructured":"Veeragandham RS, Goldin MD (1998) Surgical management of radiation-induced heart disease. Ann Thorac Surg 65:1014\u20131019. https:\/\/doi.org\/10.1016\/s0003-4975(98)00082-4","journal-title":"Ann Thorac Surg"},{"key":"10028_CR127","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3892\/mco.2018.1764","volume":"10","author":"A Sato","year":"2019","unstructured":"Sato A, Yoshihisa A, Miyata-Tatsumi M et al (2019) Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer. Mol Clin Oncol 10:37\u201342. https:\/\/doi.org\/10.3892\/mco.2018.1764","journal-title":"Mol Clin Oncol"},{"key":"10028_CR128","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/0002-8703(93)90669-Z","volume":"126","author":"L S\u00f8ndergaard","year":"1993","unstructured":"S\u00f8ndergaard L, Hildebrandt P, Lindvig K, Thomsen C, St\u0227ahlberg F, Kassis E, Henriksen O (1993) Valve area and cardiac output in aortic stenosis: quantification by magnetic resonance velocity mapping. Am Heart J 126:1156\u20131164. https:\/\/doi.org\/10.1016\/0002-8703(93)90669-Z","journal-title":"Am Heart J"},{"key":"10028_CR129","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD von Hoff","year":"1979","unstructured":"von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff A, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710","journal-title":"Ann Intern Med"},{"key":"10028_CR130","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2459\/JCM.0b013e328365afb5","volume":"15","author":"G Russo","year":"2014","unstructured":"Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L (2014) Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med 15:141\u2013146. https:\/\/doi.org\/10.2459\/JCM.0b013e328365afb5","journal-title":"J Cardiovasc Med"},{"key":"10028_CR131","doi-asserted-by":"publisher","unstructured":"Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, He J (2017) Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep 7. https:\/\/doi.org\/10.1038\/srep44877","DOI":"10.1038\/srep44877"},{"key":"10028_CR132","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN (2016) Vascular complications of cancer chemotherapy. Can J Cardiol 32:852\u2013862","journal-title":"Can J Cardiol"},{"key":"10028_CR133","doi-asserted-by":"crossref","unstructured":"Burger A, L\u00f6ffler H, Bamberg M, Rodemann HP (1998) Molecular and cellular basis of radiation fibrosis. In: International Journal of Radiation Biology. Taylor & Francis, pp 401\u2013408","DOI":"10.1080\/095530098142239"},{"key":"10028_CR134","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ccd.21681","volume":"72","author":"JA Jurado","year":"2008","unstructured":"Jurado JA, Bashir R, Burket MW (2008) Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 72:563\u2013568. https:\/\/doi.org\/10.1002\/ccd.21681","journal-title":"Catheter Cardiovasc Interv"},{"key":"10028_CR135","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981\u20131988. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"key":"10028_CR136","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel el Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. J Am Med Assoc 291:2441\u20132447. https:\/\/doi.org\/10.1001\/jama.291.20.2441","journal-title":"J Am Med Assoc"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10028-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-020-10028-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10028-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:17:02Z","timestamp":1723742222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-020-10028-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10028"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10028-y","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"15 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}